MIRA PHARMACEUTICALS, INC.
Ketamir-2
chemotherapy-induced peripheral neuropathy
Resolved
7days ago
Phase 2 readout · ~ Jun 30, 2026 estimated
What's at stake
Phase 2 trial results for Ketamir-2 in chemotherapy-induced peripheral neuropathy are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“The Company intends to submit the Phase 2a clinical study and supporting documentation to the U.S. Food and Drug Administration under its active Investigational New Drug application in the first half of 2026.”